Carlos Vargas Oliva

Carlos Vargas Oliva

Auto-generated profile, based on publicly available information

Carlos Vargas Oliva

Instituto Mexicano del Seguro Social

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
EZEréndira Pacheco Zavala
Eréndira Pacheco Zavala
COCarlos Vargas Oliva
Carlos Vargas Oliva
KBKarla Edith Santibañez Bedolla
Karla Edith Santibañez Bedolla
BOBlanca Olivia Murillo Ortiz
Blanca Olivia Murillo Ortiz
OVOctavio Martínez Villegas
Octavio Martínez Villegas
LMLauro Fabian Amador Medina
Lauro Fabian Amador Medina

18 October 2025 in Ibero Ciencias - Revista Científica y Académica
Verified
Journal Article
Open access
PDF file
MRMario Alberto Zuñiga Rios
Mario Alberto Zuñiga Rios
RGRubén Darío Arizola García
Rubén Darío Arizola García
GTGisela Berenice Orozco Torres
Gisela Berenice Orozco Torres
COCarlos Vargas Oliva
Carlos Vargas Oliva
The study aimed to determine the clinical-epidemiological profile of patients with prostate cancer assigned to Family Medicine Unit No. 47 during the 2019–2023 period. It sought to describe their clinical characteristics, associated factors, and diagnostic patterns to generate information that contributes to improving timely detection and management of this disease. Prostate cancer is the second leading cause of cancer-related death in men worldwide and nationally. In Mexico, it maintains a high incidence, highlighting the importance of early detection as a strategy to intervene in initial stages and improve prognosis. The study used a quantitative approach with an observational, retrospective, cross-sectional, and descriptive design. Records from 159 confirmed patients were reviewed, analyzing sociodemographic, clinical, and diagnostic variables through descriptive statistics. The average age was 75.2 years, with most patients being retired men and having normal weight. Hypertension was the most frequent comorbidity. Prostate-specific antigen was the most commonly used diagnostic study, while urinary urgency was the most common symptom. The results emphasized the need to strengthen screening programs for men over 50 years of age and those with risk factors. They also highlighted the importance of promoting health education, reducing stigma, and encouraging a comprehensive approach that improves prognosis and quality of life.

18 October 2025 in Ibero Ciencias - Revista Científica y Académica
Verified
Journal Article
Open access
DPDavid Antonio Ramírez Pérez
David Antonio Ramírez Pérez
GTGisela Berenice Orozco Torres
Gisela Berenice Orozco Torres
DRDulce María Román Romero
Dulce María Román Romero
MCMarco Alejandro Nezahualcóyotl León Cardoso
Marco Alejandro Nezahualcóyotl León Cardoso
COCarlos Vargas Oliva
Carlos Vargas Oliva
Background. Aging population has increased the prevalence of chronic diseases such as systemic arterial hypertension (SAH), especially in older adults. One of the main challenges in its management is achieving adequate adherence to treatment, with various factors involved, including cognitive impairment. This condition affects functions such as memory, judgment, and comprehension, negatively impacting the patient's ability to follow therapeutic instructions. Given this context, it is considered important to analyze whether there is a relationship between non-adherence and cognitive impairment. Objective. To establish the association between non-adherence to antihypertensive treatment and cognitive impairment in adults over 65 years of age. Materials and methods. An analytical cross-sectional study was conducted in 193 hypertensive patients over 65 years of age. A non-probabilistic convenience sampling method was used. Adherence was assessed using the 8-item Morisky scale (MMAS-8), and cognitive status was assessed using the Mini-Mental State Examination (MMSE). Descriptive statistics and bivariate analysis using the Chi-square test (p<0.05) were applied. Results: 49.7% of patients were non-adherent to treatment. Among them, 30% presented cognitive impairment, compared to 14% in the adherent group (p=0.006). The prevalence of comorbidities was high, with diabetes mellitus (36.6%) and dyslipidemia (6.7%) being the most prominent. Conclusion: A statistically significant association was identified between non-adherence to treatment and cognitive impairment. These findings support the need to incorporate cognitive screening into the care of hypertensive older adults to improve adherence and clinical outcomes.